Zealand Pharma A/S
Smedeland 26 B
Glostrup
DK-2600
Tel: 45-43-28-12-00
Fax: 45-43-28-12-12
Website: http://www.zp.dk/
Email: info@zp.dk
299 articles about Zealand Pharma A/S
-
Zealand Pharma and Novo Nordisk linked resources to commercialize Zegalogue for severe hypoglycemia. For that and more from a busy week across the globe, see inside.
-
Zealand Pharma to Participate in Morgan Stanley 20th Annual Global Healthcare Conference
9/7/2022
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the company will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference.
-
Zealand Pharma Announces Global License and Development Agreement with Novo Nordisk for ZEGALOGUE® (dasiglucagon)
9/7/2022
Zealand Pharma A/S announced it has entered into a global license and development agreement with Novo Nordisk A/S to commercialize ZEGALOGUE® for injection.
-
Total number of shares and voting rights in Zealand Pharma at August 31, 2022
8/31/2022
Zealand Pharma A/S announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.
-
This week's Movers & Shakers includes Tessa and Adial bringing in new CEOs, while other companies strengthened their regulatory and medical teams with key appointments
-
Zealand Pharma Appoints Henriette Wennicke as Chief Financial Officer
8/24/2022
Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the appointment of Henriette Wennicke as Zealand’s Chief Financial Officer starting November 1, 2022.
-
Zealand Pharma Announces Financial Results for the First Half of 2022
8/11/2022
Zealand Pharma A/S a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced financial results for the first half of 2022 and provided a corporate update.
-
Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the U.S.-Based Nasdaq Global Select Market
8/8/2022
Zealand Pharma Announces Voluntary Delisting of American DepositaryShares from the U.S.-Based Nasdaq Global Select Market
-
Zealand Pharma Hosts Conference Call on August 11 at 4 pm CET (10am ET) to Present Second Quarter Results for 2022
8/4/2022
Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 11, 2022 at 4 pm CET (10 am ET) following the announcement of results for the second quarter of 2022.
-
Iktos and Zealand Pharma to Develop Artificial Intelligence Technology for Peptide Drug Design
6/21/2022
Iktos, a company specialized in Artificial Intelligence for new drug design, announced a research collaboration with Zealand Pharma A/S, a biotechnology company changing lives with innovative peptide-based medicines to co-develop generative and predictive AI technologies for peptide drug design.
-
Zealand Pharma Presents Data from Phase 1 Trial of Dapiglutide at the 82nd Annual American Diabetes Association Scientific Sessions and Announces Dapiglutide to Move into Phase 2 Trial for Obesity
6/6/2022
Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), today presented data from its Phase 1 trial of dapiglutide at the 82nd Scientific Sessions of the American Diabetes Association (ADA) in New Orleans and announced it will be supporting a Phase 2 investigator-initiated clinical trial of dapiglutide in obesity anticipated to commence by early 2023.
-
Zealand Pharma to Participate in Upcoming Investor Conferences
6/3/2022
Zealand Pharma to Participate in Upcoming Investor Conferences.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Zealand Pharma Announces Appointment of David M. Kendall, M.D., as Chief Medical Officer
6/2/2022
Zealand Pharma A/S a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the appointment of David M. Kendall, M.D., as Chief Medical Officer.
-
Zealand Pharma Announces Multiple Presentations at the 82nd Annual American Diabetes Association Scientific Sessions, Including Initial Clinical Data on GLP-1/GLP-2 Dual Agonist Dapiglutide
5/31/2022
Zealand Pharma Announces Multiple Presentations at the 82nd Annual American Diabetes Association Scientific Sessions, Including Initial Clinical Data on GLP-1/GLP-2 Dual Agonist Dapiglutide.
-
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
-
Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)
5/19/2022
Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI).
-
Zealand Pharma shared positive top-line results for its second Phase III clinical trial of its congenital hyperinsulinism (CHI) drug, dasiglucagon, in pediatric patients.
-
Zealand Pharma Announces Asset Purchase Agreement with MannKind Corporation for V-Go® Insulin Delivery Device
5/17/2022
Zealand Pharma Announces Asset Purchase Agreement withMannKind Corporation forV-Go®Insulin Delivery Device
-
MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma
5/17/2022
MannKind Corporation announced that it has entered into an agreement with Zealand Pharma A/S to acquire V-Go® for $10 million, with additional sales-based milestones plus the cost of certain inventory.